Get free email updates Subscribe to the Drug Channels RSS feed Follow Drug Channels on Twitter Drug Channels

Pages

  • ABOUT
  • INDUSTRY REPORTS
  • WEBINARS
  • KEYNOTE SPEAKING
  • ADVERTISE
  • SUBSCRIBE / CONTACT

SUBSCRIBE / CONTACT


Get notified by email of new posts on Drug Channels


Follow Dr. Fein and DCI on LinkedIn


Send an email to Adam J. Fein, Ph.D.


Follow Drug Channels on Twitter


Follow Drug Channels on YouTube


MAILING ADDRESS

Drug Channels Institute c/o Pembroke Consulting, Inc.
1515 Market Street, Suite 1660
Philadelphia, PA 19102


Home
Drug Channels is written by Adam J. Fein, Ph.D. Dr. Fein is President of Drug Channels Institute, an HMP Global company. Read More...

Email Dr. Fein
Follow on LinkedIn
@DrugChannels
Drug Channels videos

PURCHASE OUR INDUSTRY REPORTS

Sponsors

Search Drug Channels

View Articles by Topic


Popular Recent Posts

  • Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market
  • The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA’s Curious Actions
  • The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead
  • Transparency Shocker: Biosimilars Are Getting Cheaper—But Hospitals and Insurers Can Make Them Expensive
  • Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

View Articles by Date

  • ▼  2024 (114)
    • ▼  November 2024 (6)
      • From Integration to AI: The Data-Driven Future of ...
      • Medicare Part D in 2025: Preferred Pharmacy Networ...
      • Drug Channels Outlook 2025 (NEW Live Video Webinar)
      • How the Perfect Storm Will Impact Patient Support ...
      • Transparency Shocker: Biosimilars Are Getting Chea...
      • How Field Reimbursement Services Help Overcome Cov...
    • ►  October 2024 (14)
    • ►  September 2024 (14)
    • ►  August 2024 (7)
    • ►  July 2024 (8)
    • ►  June 2024 (12)
    • ►  May 2024 (9)
    • ►  April 2024 (14)
    • ►  March 2024 (12)
    • ►  February 2024 (9)
    • ►  January 2024 (9)
  • ►  2023 (127)
    • ►  December 2023 (10)
    • ►  November 2023 (7)
    • ►  October 2023 (15)
    • ►  September 2023 (12)
    • ►  August 2023 (10)
    • ►  July 2023 (7)
    • ►  June 2023 (13)
    • ►  May 2023 (11)
    • ►  April 2023 (8)
    • ►  March 2023 (16)
    • ►  February 2023 (9)
    • ►  January 2023 (9)
  • ►  2022 (126)
    • ►  December 2022 (11)
    • ►  November 2022 (8)
    • ►  October 2022 (10)
    • ►  September 2022 (10)
    • ►  August 2022 (9)
    • ►  July 2022 (14)
    • ►  June 2022 (10)
    • ►  May 2022 (8)
    • ►  April 2022 (15)
    • ►  March 2022 (12)
    • ►  February 2022 (10)
    • ►  January 2022 (9)
  • ►  2021 (128)
    • ►  December 2021 (10)
    • ►  November 2021 (9)
    • ►  October 2021 (11)
    • ►  September 2021 (14)
    • ►  August 2021 (9)
    • ►  July 2021 (9)
    • ►  June 2021 (15)
    • ►  May 2021 (10)
    • ►  April 2021 (12)
    • ►  March 2021 (14)
    • ►  February 2021 (4)
    • ►  January 2021 (11)
  • ►  2020 (132)
    • ►  December 2020 (9)
    • ►  November 2020 (11)
    • ►  October 2020 (15)
    • ►  September 2020 (15)
    • ►  August 2020 (10)
    • ►  July 2020 (11)
    • ►  June 2020 (6)
    • ►  May 2020 (12)
    • ►  April 2020 (9)
    • ►  March 2020 (14)
    • ►  February 2020 (11)
    • ►  January 2020 (9)
  • ►  2019 (148)
    • ►  December 2019 (11)
    • ►  November 2019 (11)
    • ►  October 2019 (16)
    • ►  September 2019 (10)
    • ►  August 2019 (14)
    • ►  July 2019 (15)
    • ►  June 2019 (10)
    • ►  May 2019 (14)
    • ►  April 2019 (15)
    • ►  March 2019 (10)
    • ►  February 2019 (12)
    • ►  January 2019 (10)
  • ►  2018 (158)
    • ►  December 2018 (13)
    • ►  November 2018 (13)
    • ►  October 2018 (14)
    • ►  September 2018 (12)
    • ►  August 2018 (14)
    • ►  July 2018 (12)
    • ►  June 2018 (15)
    • ►  May 2018 (13)
    • ►  April 2018 (15)
    • ►  March 2018 (13)
    • ►  February 2018 (12)
    • ►  January 2018 (12)
  • ►  2017 (155)
    • ►  December 2017 (13)
    • ►  November 2017 (12)
    • ►  October 2017 (12)
    • ►  September 2017 (11)
    • ►  August 2017 (13)
    • ►  July 2017 (14)
    • ►  June 2017 (14)
    • ►  May 2017 (17)
    • ►  April 2017 (14)
    • ►  March 2017 (13)
    • ►  February 2017 (11)
    • ►  January 2017 (11)
  • ►  2016 (155)
    • ►  December 2016 (12)
    • ►  November 2016 (13)
    • ►  October 2016 (14)
    • ►  September 2016 (11)
    • ►  August 2016 (15)
    • ►  July 2016 (13)
    • ►  June 2016 (12)
    • ►  May 2016 (12)
    • ►  April 2016 (16)
    • ►  March 2016 (13)
    • ►  February 2016 (14)
    • ►  January 2016 (10)
  • ►  2015 (157)
    • ►  December 2015 (9)
    • ►  November 2015 (12)
    • ►  October 2015 (14)
    • ►  September 2015 (14)
    • ►  August 2015 (12)
    • ►  July 2015 (15)
    • ►  June 2015 (11)
    • ►  May 2015 (13)
    • ►  April 2015 (15)
    • ►  March 2015 (15)
    • ►  February 2015 (14)
    • ►  January 2015 (13)
  • ►  2014 (148)
    • ►  December 2014 (11)
    • ►  November 2014 (10)
    • ►  October 2014 (15)
    • ►  September 2014 (13)
    • ►  August 2014 (15)
    • ►  July 2014 (13)
    • ►  June 2014 (13)
    • ►  May 2014 (10)
    • ►  April 2014 (16)
    • ►  March 2014 (10)
    • ►  February 2014 (11)
    • ►  January 2014 (11)
  • ►  2013 (147)
    • ►  December 2013 (11)
    • ►  November 2013 (11)
    • ►  October 2013 (13)
    • ►  September 2013 (15)
    • ►  August 2013 (9)
    • ►  July 2013 (11)
    • ►  June 2013 (12)
    • ►  May 2013 (10)
    • ►  April 2013 (16)
    • ►  March 2013 (14)
    • ►  February 2013 (11)
    • ►  January 2013 (14)
  • ►  2012 (145)
    • ►  December 2012 (10)
    • ►  November 2012 (11)
    • ►  October 2012 (14)
    • ►  September 2012 (11)
    • ►  August 2012 (15)
    • ►  July 2012 (13)
    • ►  June 2012 (13)
    • ►  May 2012 (12)
    • ►  April 2012 (13)
    • ►  March 2012 (10)
    • ►  February 2012 (12)
    • ►  January 2012 (11)
  • ►  2011 (137)
    • ►  December 2011 (8)
    • ►  November 2011 (9)
    • ►  October 2011 (12)
    • ►  September 2011 (14)
    • ►  August 2011 (13)
    • ►  July 2011 (10)
    • ►  June 2011 (11)
    • ►  May 2011 (15)
    • ►  April 2011 (11)
    • ►  March 2011 (12)
    • ►  February 2011 (11)
    • ►  January 2011 (11)
  • ►  2010 (139)
    • ►  December 2010 (8)
    • ►  November 2010 (12)
    • ►  October 2010 (11)
    • ►  September 2010 (13)
    • ►  August 2010 (12)
    • ►  July 2010 (10)
    • ►  June 2010 (16)
    • ►  May 2010 (11)
    • ►  April 2010 (13)
    • ►  March 2010 (12)
    • ►  February 2010 (10)
    • ►  January 2010 (11)
  • ►  2009 (108)
    • ►  December 2009 (11)
    • ►  November 2009 (10)
    • ►  October 2009 (14)
    • ►  September 2009 (12)
    • ►  July 2009 (2)
    • ►  June 2009 (10)
    • ►  May 2009 (11)
    • ►  April 2009 (10)
    • ►  March 2009 (10)
    • ►  February 2009 (9)
    • ►  January 2009 (9)
  • ►  2008 (94)
    • ►  December 2008 (6)
    • ►  November 2008 (5)
    • ►  October 2008 (9)
    • ►  September 2008 (15)
    • ►  August 2008 (1)
    • ►  July 2008 (2)
    • ►  June 2008 (13)
    • ►  May 2008 (9)
    • ►  April 2008 (9)
    • ►  March 2008 (8)
    • ►  February 2008 (9)
    • ►  January 2008 (8)
  • ►  2007 (115)
    • ►  December 2007 (8)
    • ►  November 2007 (13)
    • ►  October 2007 (10)
    • ►  September 2007 (13)
    • ►  August 2007 (7)
    • ►  July 2007 (16)
    • ►  June 2007 (7)
    • ►  May 2007 (8)
    • ►  April 2007 (6)
    • ►  March 2007 (9)
    • ►  February 2007 (7)
    • ►  January 2007 (11)
  • ►  2006 (57)
    • ►  December 2006 (7)
    • ►  November 2006 (9)
    • ►  October 2006 (9)
    • ►  September 2006 (10)
    • ►  August 2006 (5)
    • ►  July 2006 (5)
    • ►  June 2006 (8)
    • ►  May 2006 (4)

Drug Channels in the News

Is The Time Right For Congressional Action On #340B? Forbes

Lawmakers want FTC to probe big PBMs over private-label biosimilar deals STAT

Specialty Pharmacy: The Trends Shaping Best Practices Pharmaceutical Commerce

Drug Channels Leadership Forum to feature powerhouse lineup in event hosted by HMP Global’s Drug Channels Institute EIN Presswire

Federal agency opposes J&J's new 340B discount model, promises to take 'actions as warranted' Endpoints

The Next 340B Battle: Discount Duplication With Medicare Negotiated Prices The Pink Sheet

The Anti-Competitive Middlemen Harming Pharmacies And Patients Forbes

IRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels 340B Report

The Opaque Industry Secretly Inflating Prices for Prescription Drugs The New York Times

Navigating the Inflation Reduction Act's Impact on Drug Pricing and Health Care First Report Managed Care

Biden’s War on Medicare RealClear Policy

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene? The Pink Sheet

Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35 STAT

Latest Formulary Exclusions from Top PBMs Demonstrate Issues in the Drug Pricing Landscape First Report Managed Care

Drug Channel Entities Are Undergoing Raft of Changes Spotlight on Market Access

CVS Removes Humira From Formulary — But the Fine Print Is Key Radar on Drug Benefits

CVS Plans to Overhaul How Much Drugs Cost The Wall Street Journal

Cigna-Humana Merger Is Likely to Face Antitrust Challenge The Wall Street Journal

Amazon Once Inspired Fear in the Health-Care Industry. No Longer Bloomberg

Why Your Neighborhood Pharmacy Isn’t So Friendly Anymore The Wall Street Journal

Rite Aid Bankruptcy Follows Years of PBM Misadventure Radar on Drug Benefits

What CVS Stands to Gain by Setting Up Biosimilar Subsidiary Cordavis MedCity News

Ohio senator says Medicare drug cost negotiations will save money. Others aren't so sure WSYX

Drug Benefit Firms Devise New Fees That Go to Them, Not Clients Bloomberg

CVS Health Dives As Blue Shield Of California Taps Mark Cuban, Amazon In Challenge To PBM Model Investor's Business Daily

A Big Health Insurer Is Ripping Up the Playbook on Drug Pricing The Wall Street Journal

Patients already paying price for PBMs diverting copay cash meant for needy ABC6

PBMs Keep New Biosimilars on Equal Footing With Best-Selling Humira, Radar on Drug Benefits

Accumulators, Maximizers, Alternative Funding Models Contribute to ‘Doom Loop of Specialty Drug Benefits’ AIS Health

How to Beat the Rising Cost of Prescription Drugs Consumer Reports

Average salaries for retail pharmacists grows for first time in three years MM+M

Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts STAT

The Healthcare World According to Fein Managed Healthcare Executive

Drug Middlemen Accused of Price Fixing by Ohio Attorney General The Wall Street Journal

Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines STAT

A Softbank-backed pharmacy startup is working to tackle a $300-billion-a-year prescription drug crisis Fortune

Tackling cancer while battling the insurance system The Washington Post

'It is legal extortion': Diabetics pay steep price for insulin as rebates drive up costs USA Today

INDUSTRY NEWS AND BLOGS

  • STAT
    First U.S. case of new mpox strain detected in California
  • Endpoints
    Trump picks RFK Jr. for HHS; AbbVie's psych implosion; Merck tries staving off Summit; and more
  • PR Newswire: Health Insurance
    Oscar Health Announces New Health Insurance Options in New Jersey in 2025
  • Drug Store News - Pharmacy
    Walgreens, Dion’s Dream Chicago host Dream Vault Smart Locker in Gage Park store
  • Fierce Pharma
    AbbVie doles out awards to support career goals of 20 people living with migraines
  • PCMA
    Big Pharma’s Latest Ad Binge A Critical Reminder: Policies Targeting PBMs Would Hand Drug Companies A Profit Windfall At The Expense Of Seniors And Taxpayers
  • MMIT Network
    Part D Redesign, MFPs, Plan Changes Will Impact Contracting Strategies
  • Biosimilars Review & Report
    New Denosumab Applications Filed, New Ustekinumab Biosimilar Approved
  • RxTrace
    DSCSA Exemptions: What You Need to Know for Compliance
  • Chain Drug Review
    CVS Health names Heidi Capozzi EVP, Chief People Officer
  • Eye on FDA
    FDA Adds New AdComm to Address Genetic Metabolic Diseases
  • The Catalyst (PhRMA)
    Three things to know from the latest Patient Experience Survey
  • Health Business Group
    Interview with Aktana CEO David Ehrlich
Show 10 Show All
DISCLAIMER
The analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by HMP Omnimedia, LLC, Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and HMP Omnimedia, LLC, Drug Channels Institute, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. HMP Omnimedia, LLC, and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by HMP Omnimedia, LLC, Drug Channels Institute, or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Drug Channels Institute or the author. Neither Drug Channels Institute nor the author endorse or approve of their content. Drug Channels Institute and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site. The material on this site is protected by copyright law. Unauthorized reproduction or distribution of this material may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This material may be cited in non-advertising commercial documents with full and appropriate attribution, but may not be used in any advertisements without prior written permission from Drug Channels Institute. We do not intend to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws. We do not permit our articles to be republished without prior written permission.

The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees.

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved.

Drug Channels® is a registered trademark of HMP Global.

Privacy Policy | Terms of Use